ClinicalTrials.Veeva

Menu

Supportive Measures in Treatment of Aluminum Phosphide Poisoning

A

Assiut University

Status and phase

Completed
Phase 4

Conditions

Using New Protocol to Prove the Role of N-acetyl Cysteine and Adequate Supportive Measures in Aluminum Phosphide Poisoning
Detection of Different Prognostic Factors and Their Relation With the Outcome

Treatments

Drug: N-acetyl cysteine

Study type

Interventional

Funder types

Other

Identifiers

NCT03879356
AluminumPhosphideAssiut

Details and patient eligibility

About

Aluminum phosphide poisoning (ALP) is a global public health problem, and self-poisoning accounts for one-third of the world's suicide rate. In fact, in some parts of developing countries, pesticide poisoning causes more deaths than infection. ALP is very common in our government and the prognosis of the cases is usually so bad. Toxicity by ALP is caused by the liberation of phosphine gas, which causes cell hypoxia due to inhibition of oxidative phosphorylation leading to circulatory failure.

Full description

Aluminum phosphide poisoning is a major problem, accounting for many Emergency Unit visits and hospitalization, the incidence of aluminum phosphide poisoning increasing in the last few years.

ALP is used as pesticides for many years to protect grains in stores and during its transportation. The availability of these tablets and their low cost make it an easy and common method of suicide in our country with the increasing incidence of social and financial problems that face the youth.

In management, the main objective is to provide effective oxygenation, ventilation, and circulation until phosphine is excreted. All patients of severe ALP poisoning require continuous invasive hemodynamic monitoring and early resuscitation with fluid and vasoactive agents. N- acetylcysteine as an antioxidant and cytoprotective agent reduces myocardial oxidative injury and increase survival time. Magnesium sulfate helps in scavenging free radicals through glutathione (GSH) recovery hence is effective as a parenteral antioxidant in this poisoning as well as has been tried for its general membrane stabilizing effect in cardiac cells .

Death after 24 hours occurs usually owing to shock, cardiac arrhythmia, metabolic acidosis, and acute respiratory distress syndrome.

Enrollment

44 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All the cases with the primary diagnosis of Aluminum phosphide toxicity will be included in the study.
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion criteria

  • Patients with a history of any chronic disease (renal and hepatic).
  • Patients refuse to participate in the study.
  • Aged less than 18 years

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

44 participants in 1 patient group

Aluminum phosphide patients
Other group
Description:
effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
Treatment:
Drug: N-acetyl cysteine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems